Canadian psychedelic drug producer Optimi Health (OPTH.US) set the IPO price at 6-8 USD/share, aiming to raise 15 million USD.

Headquartered in Canada, the pharmaceutical company Optimi Health (OPTH.US), which focuses on MDMA and psilocybin, announced its IPO terms last Friday. The company, based in Princeton, Canada, plans to issue 2.1 million shares of stock at a price range of $6 to $8 per share, aiming to raise $15 million. The company is a licensed pharmaceutical manufacturer in Canada, producing controlled substances such as MDMA and psilocybin. It operates two production facilities in British Columbia and holds multiple licenses to produce, import, and distribute these substances within legal limits. Its approved operations range from extracting active ingredients from plants to processing and supplying hallucinogens in regulated quantities. Established in 2020, Optimi Health plans to list on the Nasdaq under the ticker symbol OPTH. The exclusive book-running manager for this IPO is Joseph Gunnar.